Article

The Use of Stereotactic Body Radiation Therapy in Gastrointestinal Malignancies in Locally Advanced and Metastatic Settings

Hematology-Oncology, Northwestern University, Chicago, IL, USA.
Clinical Colorectal Cancer (Impact Factor: 2.91). 07/2010; 9(3):136-43. DOI: 10.3816/CCC.2010.n.018
Source: PubMed

ABSTRACT Gastrointestinal (GI) malignancies are a major cause of cancer morbidity and mortality, with an estimated 275,720 cases and 135,800 deaths in 2009. Treatment of GI malignancies presents a challenge both in the localized and metastatic setting and in formulating new ways to improve local disease control and ultimately overall survival. Among conventional modalities of treatment, such as systemic chemotherapy, fractionated radiation therapy, surgical resection, and nonsurgical invasive means, a new technology has emerged: stereotactic body radiation therapy (SBRT). Its origins stem from the intracranial stereotactic radiosurgery developed in 1950s for the treatment of patients with intracranial malignancies. SBRT is a new and innovative way of delivering high-dose radiation to the extracranial tumor targets in one or few fractions with a high degree of precision. Although SBRT technology such as CyberKnife and Novalis are becoming increasingly popular and widely used, there are limited data that provide comparison with conventional therapy, and no randomized, prospective, multicenter studies that having been conducted in areas of GI malignancies. Current studies that provide data on SBRT use consist of small cohorts of patients, making any assessment of survival inadequate. This article is a technical review of SBRT and will focus on the origins and principles of SBRT, utilization of SBRT technology in local and metastatic settings in GI malignancies, and the examination of local control, median survival, and toxicities. It will review available data and will discuss future directions in the GI field.

0 Bookmarks
 · 
43 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Solitary fibrous tumor is a rare tumor occurring in almost every anatomic location of human body; however, reports of malignant solitary fibrous tumor in the nasal and paranasal area are especially rare. In this report, we describe a case of non-recurrent malignant solitary fibrous tumor of the nasal and paranasal area. Methods: The patient was initially treated with nasal and paranasal tumor cytoreductive surgery, followed by post-operative three-dimensional conformal intensity modulated radiation therapy (dynamic MLC Varian 600CD Linac, inversely optimized by the Eclipse system) and stereotactic body radiation therapy to provide a radical cure for residual tumor. Results: The tumor of the nasal and paranasal area was effectively treated and the integrity of the right eye kept. There were no signs of recurrence after four and a half years of further follow-up. Conclusions: This is the first attempt to successfully combine cytoreductive surgery with intensity modulated radiation therapy and stereotactic body radiation therapy together to treat solitary fibrous tumor of the nasal and paranasal area, which may provide a potential strategy for the treatment of similar cases.
    Japanese Journal of Clinical Oncology 08/2014; 44(10). DOI:10.1093/jjco/hyu100 · 1.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review article, we review the current literature addressing the use of stereotactic body radiation therapy (SBRT) in non-hepatobiliary gastrointestinal malignancies. For many gastrointestinal malignancies, the desire to treat large fields encompassing nodal drainage and micrometastatic disease has precluded the use of stereotactic body radiation therapy for most definitive cases. However, the use of SBRT in locally advanced pancreatic cancer (LAPC) as well as in the treatment of metastatic abdominal lymph nodes has shown excellent local control rates. In carefully selected patients, local control in LAPC has been achieved with SBRT with minimal side effects. Toxicity in these patients has most closely correlated with the dose and volume of irradiated duodenum and small bowel. Similar patterns of excellent local control with minimal side effects have also been seen in the treatment of abdominal lymph node metastases as well as gastric and rectal cancer recurrence.
    12/2012; DOI:10.1007/s13566-012-0027-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: The purpose of this study is to identify the predictors for severe intestinal toxicity (IT) in patients with abdominopelvic malignancies treated with three fractions of stereotactic ablative radiotherapy (SABR). METHODS: From 2001 to 2011, 202 patients with abdominopelvic malignancies were treated with curative-intent SABR. Among these, we retrospectively reviewed the clinical records of 55 patients with the presence of the intestine that received a dose ≥20 % of the prescribed dose. The total dose ranged from 33 to 60 Gy in three fractionations (median dose, 45 Gy). We analyzed the clinical and dosimetric parameters for severe IT ≥ grade 3 according to the National Cancer Institute Common Toxicity Criteria v4.0: V 20-35 (volume of the intestine that received xGy) and D max (maximum point dose). RESULTS: Severe IT was found in six patients (the median time, 3 months). V 25 was the best dosimetric predictor for severe IT (P = 0.004). With V 25 ≤ 20 ml, severe IT decreased from 50 to 4 %. SABR duration was the best clinical predictor. Severe IT decreased in patients who received SABR at 4-8 days than on three consecutive days (0 vs. 18 %, P = 0.037). CONCLUSIONS: Following three fractions of SABR, V 25 is a valuable predictor of severe IT. And SABR would be conducted with a treatment interval of at least 48 h if possible.
    International Journal of Colorectal Disease 06/2013; 28(12). DOI:10.1007/s00384-013-1717-6 · 2.24 Impact Factor